{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:54:52Z","timestamp":1780563292589,"version":"3.54.1"},"reference-count":171,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01189","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T15:17:25Z","timestamp":1531927045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin"],"prefix":"10.3389","volume":"9","author":[{"given":"A. Razzaque","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Kaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"B1","unstructured":"Autoimmune Disease Statistics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B3","first-page":"375","article-title":"Corticosteroids: a review with emphasis on complications of prolonged systematic therapy","volume":"62","author":"Truhan","year":"1989","journal-title":"Ann Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1749-6632.2002.tb04205.x","article-title":"Glucocorticoids in rheumatoid arthritis: effects on erosions and bone","volume":"966","author":"Bijlsma","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2119\/2008-00066.Zhang","article-title":"Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self\u2013reactive B cells","volume":"14","author":"Zhang","year":"2008","journal-title":"Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14737175.2017.1245616","article-title":"Anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"17","author":"Moreno Torres","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.autrev.2009.02.008","article-title":"Long term treatment of rheumatoid arthritis with rituximab","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/rheumatology\/kem164","article-title":"Repeated B-cell depletion in clinical practice","volume":"46","author":"Edwards","year":"2007","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MJT.0b013e318258905e","article-title":"Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up","volume":"20","author":"Routy","year":"2013","journal-title":"Am J Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11481-015-9646-5","article-title":"Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID)","volume":"11","author":"Rommer","year":"2016","journal-title":"J Neuroimmune Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","article-title":"Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy","volume":"189","author":"Winter","year":"2012","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2015","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"L14104","DOI":"10.1073\/pnas.0700506104","article-title":"Intravenous immunoglobulin IVIG protects the brain against experimental stroke by preventing complement-mediated neuronal cell death","volume":"104","author":"Arumugam","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2015.00469","article-title":"Induction of regulatory T cells by intravenous immunoglobulin: a bridge between adaptive and innate immunity","volume":"6","author":"Kaufman","year":"2015","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1517\/13543784.13.8.1019","article-title":"Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy","volume":"13","author":"Ahmed","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.intimp.2005.11.005","article-title":"IVIg: contents, properties and methods of industrial production\u2014evolving closer to a more physiologic product","volume":"6","author":"Martin","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/1061186X.2013.875030","article-title":"Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering","volume":"22","author":"Wang","year":"2014","journal-title":"J Drug Target"},{"key":"B28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/jnnp-2017-316427","article-title":"Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial","volume":"88","author":"Kuwabara","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/11533290-000000000-00000","article-title":"Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety","volume":"11","author":"G\u00fcrcan","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1046\/j.1468-3083.2003.00714.x","article-title":"Influence of intravenous immunoglobulin therapy of autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid","volume":"17","author":"Sami","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","first-page":"377","article-title":"Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris","volume":"13","author":"Sami","year":"2003","journal-title":"Eur J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/clim.2002.5278","article-title":"Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus","volume":"105","author":"Sami","year":"2002","journal-title":"Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1365-2249.2002.01942.x","article-title":"Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human \u03b16 integrin","volume":"129","author":"Sami","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1076\/0271-3683(200008)2121-VFT646","article-title":"Influence of intravenous immunoglobulin therapy on serum levels of anti-\u03b24 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity","volume":"21","author":"Letko","year":"2000","journal-title":"Curr Eye Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2015.02.038","article-title":"Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis","volume":"26","author":"Nguyen","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.molmed.2015.01.005","article-title":"Molecular and immunological biomarkers to predict IVIg response","volume":"21","author":"Galeotti","year":"2015","journal-title":"Trends Mol Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"27816","DOI":"10.18632\/oncotarget.4816","article-title":"Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1056\/NEJMc1508234","article-title":"Long-term remissions in recalcitrant pemphigus vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid","volume":"117","author":"Foster","year":"2010","journal-title":"Ophtomology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/09546634.2016.1179711","article-title":"Long term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy","volume":"28","author":"Oktem","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/ICO.0000000000001024","article-title":"Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis \u2013 an interventional case series","volume":"35","author":"Steger","year":"2016","journal-title":"Cornea"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e66308","DOI":"10.1371\/journal.pone.0066308","article-title":"Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review","volume":"8","author":"Castillo-Trivino","year":"2013","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1177\/0300060517695646","article-title":"Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura","volume":"45","author":"Chen","year":"2017","journal-title":"J Int Med Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The Multiple Pathways to Autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/jid.2008.240","article-title":"B cells and immunological tolerance","volume":"129","author":"Manjarrez-Ordu\u00f1o","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/bmj.321.7253.93","article-title":"Science, medicine, and the future: tolerance and autoimmunity","volume":"321","author":"Mackay","year":"2000","journal-title":"BMJ"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1172\/JCI45790","article-title":"The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans","volume":"121","author":"Menard","year":"2011","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1172\/JCI78083","article-title":"Checkpoints that control B cell development","volume":"125","author":"Melchers","year":"2015","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.clim.2012.10.005","article-title":"The role of B lymphocytes in the progression from autoimmunity to autoimmune disease","volume":"146","author":"Salinas","year":"2013","journal-title":"Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1016\/j.febslet.2010.04.057","article-title":"The pre-B cell receptor checkpoint","volume":"584","author":"M\u00e5rtensson","year":"2010","journal-title":"FEBS Lett"},{"key":"B59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"a007146","DOI":"10.1101\/cshperspect.a007146","article-title":"Central B-cell tolerance: where selection begins","volume":"4","author":"Pelanda","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1084\/jem.20150585","article-title":"Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome","volume":"212","author":"Kolhatkar","year":"2015","journal-title":"J Exp Med"},{"key":"B62","first-page":"53","article-title":"Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases","volume":"34","author":"Alexander","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0952-7915(02)00356-4","article-title":"Humoral immunity and long-lived plasma cells","volume":"14","author":"Manz","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signaling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3324\/haematol.2015.137273","article-title":"A distinct plasmablast and na\u00efve B-cell phenotype in primary immune thrombocytopenia","volume":"101","author":"Flint","year":"2016","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","article-title":"Plasma cell survival is mediated by synergistic effects of cytokines and adhesion \u2013 dependent signals","volume":"171","author":"Cassese","year":"2003","journal-title":"J Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2215\/CJN.09430915","article-title":"B cells, antibodies, and more","volume":"11","author":"Hoffman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1002\/art.20519","article-title":"Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus","volume":"50","author":"Hutloff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B69","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7555\/JBR.29.20150035","article-title":"Translating transitions \u2013 how to decipher peripheral human B cell development","volume":"29","author":"Bemark","year":"2015","journal-title":"J Biomed Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.immuni.2007.12.004","article-title":"Sites and stages of autoreactive B cell activation and regulation","volume":"28","author":"Shlomchik","year":"2008","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nri822","article-title":"T-cell signalling and autoimmunity: molecular mechanisms of disease","volume":"2","author":"Ohashi","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.0105-2896.2009.00855.x","article-title":"Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of toll-like receptors in immunity","volume":"233","author":"Lampropoulou","year":"2010","journal-title":"Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/art.24498","article-title":"Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes","volume":"60","author":"Rochas","year":"2009","journal-title":"Arthiritis Rheum"},{"key":"B74","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.4049\/jimmunol.168.7.3165","article-title":"Germinal center B cells constitute a predominant physiological source of IL-4: implication for Th2 development in vivo","volume":"168","author":"Johansson-Lindbom","year":"2002","journal-title":"J Immunol"},{"key":"B76","first-page":"11","article-title":"Understanding B cell biology drugs targeting B cells in autoimmune diseases","volume-title":"Milestones in Drug Therapy","author":"Naradkian","year":"2014"},{"key":"B77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/82717","article-title":"Reciprocal regulation of polarized cytokine production by effector B and T cells","volume":"1","author":"Harris","year":"2000","journal-title":"Nat Immun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B79","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-065X.2008.00627.x","article-title":"Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis","volume":"223","author":"Silverman","year":"2008","journal-title":"Immunol Rev"},{"key":"B82","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.coi.2006.03.004","article-title":"Stromal niches, plasma cell differentiation and survival","volume":"18","author":"Moser","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B87","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1002\/art.24722","article-title":"Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment","volume":"60","author":"Muhammad","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B90","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","article-title":"The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"50","author":"Cambridge","year":"2014","journal-title":"J Autoimmun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1016\/j.febslet.2011.07.043","article-title":"Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis","volume":"585","author":"Chavele","year":"2011","journal-title":"FEBS Lett"},{"key":"B92","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell\u2013depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar2789","article-title":"Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis","volume":"11","author":"Rehnberg","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1182\/blood-2004-01-0346","article-title":"Human blood IgM \u201cmemory\u201d B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire","volume":"104","author":"Weller","year":"2004","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.4049\/jimmunol.177.6.3728","article-title":"A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation","volume":"177","author":"Fecteau","year":"2006","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.4049\/jimmunol.178.10.6624","article-title":"A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus","volume":"178","author":"Wei","year":"2007","journal-title":"J Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1182\/blood-2011-04-345579","article-title":"Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways","volume":"118","author":"Berkowska","year":"2011","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1002\/art.22020","article-title":"Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms","volume":"54","author":"Silverman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B102","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar3770","article-title":"Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity","volume":"14","author":"Teng","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-live dautoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B104","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","article-title":"Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy","volume":"4","author":"Mah\u00e9vas","year":"2013","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1136\/annrheumdis-2013-203455","article-title":"Autoantibodies from long-lived \u2018memory\u2019 plasma cells of NZB\/W mice drive immune complex nephritis","volume":"72","author":"Cheng","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1345\/aph.1R574","article-title":"Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab","volume":"47","author":"Shetty","year":"2013","journal-title":"Ann Pharmacother"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B110","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/cei.12472","article-title":"Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura","volume":"179","author":"Becerra","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1186\/ar3901","article-title":"B lymphocytetyping for prediction of clinical response to rituximab","volume":"14","author":"Brezinschek","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1136\/ard.2010.131326","article-title":"B-cell activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy","volume":"69","author":"de la Torre","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2011.00012","article-title":"PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders","volume":"2","author":"Van Zelm","year":"2011","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fimmu.2016.00077","article-title":"B cell development in the bone marrow is regulated by homeostatic feedback exerted by mature B cells","volume":"7","author":"Shahaf","year":"2016","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/08916934.2013.838563","article-title":"Preliminary analysis of mortality associated with rituximab use in autoimmune diseases","volume":"46","author":"Shetty","year":"2013","journal-title":"Autoimmunity"},{"key":"B117","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review serious adverse events associated with the use of rituximab \u2013 a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"B118","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early B cell tolerance checkpoint","volume":"126","author":"Chamberlain","year":"2016","journal-title":"J Clin Invest"},{"key":"B119","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.4049\/jimmunol.1301260","article-title":"Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production","volume":"192","author":"Tjon","year":"2014","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1006\/clim.2001.5061","article-title":"Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production","volume":"100","author":"Bhol","year":"2001","journal-title":"Clin Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effects in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"B122","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20192-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.4049\/jimmunol.1201965","article-title":"Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T ells and interferes with their trafficking to the central nervous system, implicating sphingosine-1tareget of rapamycin axis","volume":"190","author":"Othy","year":"2013","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/eji.1830231133","article-title":"Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis","volume":"23","author":"Dietrich","year":"1993","journal-title":"Eur J Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","article-title":"Region meditated selection of autoreactive repertoire by intravenous immunoglobulin IVIG","volume":"139","author":"Kazatchkine","year":"1994","journal-title":"Immunol Rev"},{"key":"B128","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.1073\/pnas.88.13.5917","article-title":"The population dynamics of antibodies in normal and autoimmune individuals","volume":"88","author":"Varela","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B129","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1096\/fj.01-0953hyp","article-title":"Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system","volume":"8","author":"Marchlonis","year":"2002","journal-title":"FASEB J"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/intimm\/dxn090","article-title":"Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal regulated kinases 1 and 2","volume":"20","author":"Dussault","year":"2008","journal-title":"Int Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1034\/j.1600-065X.2003.00055.x","article-title":"The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease","volume":"194","author":"O\u2019Connor","year":"2003","journal-title":"Immunol Rev"},{"key":"B132","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1538-7836.2009.03420.x","article-title":"New insight into the mechanism of action of IVIg: the role of dendritic cells","volume":"7","author":"Crow","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B133","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1172\/JCI114483","article-title":"Normal immunoglobulin for therapeutic use contain antiidiotypic specificities against and immunoglobulin antibodies","volume":"85","author":"Dietrich","year":"1990","journal-title":"J Clin Invest"},{"key":"B134","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII by high dose intravenous immunoglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"B135","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3109\/08916934.2012.665527","article-title":"B cells as effectors and regulators of autoimmunity","volume":"45","author":"Mari\u00f1o","year":"2012","journal-title":"Autoimmunity"},{"key":"B136","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2249.2009.04081.x","article-title":"The other side of immunoglobulin G: suppressor of inflammation","volume":"160","author":"Aschermann","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"i92","DOI":"10.1136\/ard.2009.117101","article-title":"The pro and anti-inflammatory activities of immunoglobulin G","volume":"69","author":"Lux","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B138","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10875-007-9082-2","article-title":"BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer","volume":"27","author":"Le Pottier","year":"2007","journal-title":"J Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1007\/s10875-010-9394-5","article-title":"Immunomodulation by intravenous immunoglobulin: role of regulatory T cells","volume":"30","author":"Maddur","year":"2010","journal-title":"J Clin Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"13381","DOI":"10.1038\/ncomms13381","article-title":"IgD attenuates the IgM-induced anergy response in transitional and mature B cells","volume":"7","author":"Sabouri","year":"2016","journal-title":"Nat Commun"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2009-12-261461","article-title":"IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes","volume":"116","author":"S\u00e9\u00eft\u00e9","year":"2010","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.4049\/jimmunol.163.5.2732","article-title":"Biased VH gene usage in early lineage human B cells: evidence for preferential Ig gene rearrangement in the absence of selection","volume":"163","author":"Rao","year":"1999","journal-title":"J Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2249.2000.01229.x","article-title":"IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ-line gene origin as in autoimmune thrombocytopenia","volume":"121","author":"Hoffmann","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1002\/1529-0131(200012)43:12<2722::AID-ANR12>3.0.CO;2-N","article-title":"Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin","volume":"43","author":"Osei","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int Immunol"},{"key":"B146","first-page":"291","article-title":"The effects of anti-idiotypic antibody on antibody production and apoptosis of anti-dsDNA antibody producing cells","volume":"21","author":"Lee","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"B148","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jbspin.2010.09.016","article-title":"Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology","volume":"78","author":"Samson","year":"2011","journal-title":"Joint Bone Spine"},{"key":"B149","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in patients with pemphigus","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/CDLI.8.5.859-863.2001","article-title":"Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases","volume":"8","author":"Hemming","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"B152","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","article-title":"Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"B153","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B154","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jiac.2016.01.006","article-title":"Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice","volume":"22","author":"Shimizu","year":"2016","journal-title":"J Infect Chemother"},{"key":"B155","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.amsu.2015.07.017","article-title":"Intravenous immunoglobulin in necrotizing fasciitis \u2013 a case report and review of recent literature","volume":"4","author":"Koch","year":"2015","journal-title":"Ann Med Surg (Lond)"},{"key":"B156","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.idc.2011.07.005","article-title":"Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases","volume":"25","author":"Hsu","year":"2011","journal-title":"Infect Dis Clin North Am"},{"key":"B157","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0928-8244(03)00304-3","article-title":"Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia","volume":"40","author":"Aghamohammadi","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ejim.2014.05.002","article-title":"Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis?","volume":"25","author":"Di Rosa","year":"2014","journal-title":"Eur J Intern Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.ijantimicag.2015.10.013","article-title":"Endogenous immunoglobulins and sepsis: new perspectives for guiding replacement therapies","volume":"46","author":"Bermejo-Martin","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"B160","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S0378-3782(14)50013-8","article-title":"Immunoglobulins in neonatal sepsis: has the final word been said?","volume":"90","author":"Capasso","year":"2014","journal-title":"Early Hum Dev"},{"key":"B161","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.jvca.2005.05.003","article-title":"Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery","volume":"19","author":"Buda","year":"2005","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"B162","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1053\/j.jvca.2015.08.025","article-title":"Effect of IgM-enriched immunoglobulin as adjunctive therapy in a patient following sepsis after open thoracoabdominal aortic aneurysm repair","volume":"30","author":"Kukic","year":"2016","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"B163","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jinf.2015.04.003","article-title":"Intravenous immunoglobulin use in septic shock patients after emergency laparotomy","volume":"71","author":"Tagami","year":"2015","journal-title":"J Infect"},{"key":"B164","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tmrv.2016.06.006","article-title":"Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy","volume":"31","author":"Windegger","year":"2017","journal-title":"Transfus Med Rev"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"B166","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","article-title":"Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation","volume":"32","author":"Ueda","year":"2018","journal-title":"Blood Rev"},{"key":"B167","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1016\/j.transproceed.2006.10.041","article-title":"Immunoglobulin induction therapy in renal transplant recipients: effects on immunoglobulin and regulatory antibody levels","volume":"38","author":"Staak","year":"2006","journal-title":"Transplant Proc"},{"key":"B168","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcrc.2005.03.003","article-title":"Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (pentaglobin) in the treatment of severe sepsis and septic shock","volume":"20","author":"Neilson","year":"2005","journal-title":"J Crit Care"},{"key":"B169","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First line rituximab combined with short term prednisone versus prednisone alone for the treatment of pemphigus (ritux 3); a prospective multicentre, parallet-group, open label randomized trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B170","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.imlet.2006.10.009","article-title":"Lymphocyte numbers and subsets in human blood. Do they mirror the situation in all organs?","volume":"108","author":"Blum","year":"2007","journal-title":"Immunol Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T20:37:17Z","timestamp":1693773437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":171,"alternative-id":["10.3389\/fimmu.2018.01189"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01189","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"article-number":"1189"}}